Clinical Trial Update: A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Innocrin's Phase 2 study evaluating the oral agent VT-464 in castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• VT-464

Snippet

Sponsor: Innocrin Pharmaceutical | Conditions: Castration-resistant Prostate Cancer, CRPC | Phase 2 | Status: COMPLETED